ProKidney Corp (NASDAQ: PROK) stock jumped 45.45% on Monday to $1.76 against a previous-day closing price of $1.21. With 6.34 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.75 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.8300 whereas the lowest price it dropped to was $1.2700. The 52-week range on PROK shows that it touched its highest point at $14.19 and its lowest point at $1.12 during that stretch. It currently has a 1-year price target of $9.60. Beta for the stock currently stands at 0.95.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PROK was up-trending over the past week, with a rise of 10.00%, but this was down by -0.56% over a month. Three-month performance dropped to -81.65% while six-month performance fell -82.42%. The stock lost -82.47% in the past year, while it has lost -74.34% so far this year. A look at the trailing 12-month EPS for PROK yields -0.58 with Next year EPS estimates of -0.69. For the next quarter, that number is -0.16. This implies an EPS growth rate of -162.49% for this year and -14.50% for next year.
Float and Shares Shorts:
At present, 61.54 million PROK shares are outstanding with a float of 35.40 million shares on hand for trading. On Oct 30, 2023, short shares totaled 9.87 million, which was 14.73% higher than short shares on Sep 28, 2023. In addition to Dr. Timothy A. Bertram D.V.M., Ph.D. as the firm’s Founder, CEO & Director, Dr. Deepak Jain Ph.D. serves as its Chief Operating Officer.
Through their ownership of 65.36% of PROK’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 31.39% of PROK, in contrast to 24.72% held by mutual funds. Shares owned by individuals account for 23.25%. As the largest shareholder in PROK with 16.47% of the stake, Morgan Stanley Investment Managem holds 10,144,599 shares worth 10,144,599. A second-largest stockholder of PROK, GBM Administradora de Activos, SA, holds 4,482,500 shares, controlling over 7.28% of the firm’s shares. Suvretta Capital Management LLC is the third largest shareholder in PROK, holding 3,867,843 shares or 6.28% stake. With a 4.48% stake in PROK, the Morgan Stanley Instl. Fund-Growth is the largest stakeholder. A total of 2,756,872 shares are owned by the mutual fund manager. The Fondo Administrado 5 SA de CV FIR, which owns about 3.95% of PROK stock, is the second-largest Mutual Fund holder. It holds 2,432,500 shares valued at 3.96 million. Morgan Stanley Invt. Fds. – US Gr holds 2.35% of the stake in PROK, owning 1,444,084 shares worth 2.35 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PROK since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With PROK analysts setting a high price target of $15.00 and a low target of $6.00, the average target price over the next 12 months is $9.60. Based on these targets, PROK could surge 752.27% to reach the target high and rise by 240.91% to reach the target low. Reaching the average price target will result in a growth of 445.45% from current levels.
Summary of Insider Activity:
Insiders traded PROK stock several times over the past three months with 2 Buys and 8 Sells. In these transactions, 5,426,055 shares were bought while 7,701,928 shares were sold. The number of buy transactions has increased to 3 while that of sell transactions has risen to 9 over the past year. The total number of shares bought during that period was 6,283,555 while 10,788,928 shares were sold.